Patents by Inventor Deborah M. Sherman
Deborah M. Sherman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110136772Abstract: Compositions particularly useful as coatings for solid dosage forms of therapeutic agents are provided, as are solid dosage forms comprising such coatings, processes for preparing such solid dosage forms, and the products of those processes. The coating compositions generally provide excellent strength and resistance to cracking, even when applied to flexible/swellable tablet cores such as hydrogel-type cores. The compositions also exhibit excellent odor-blocking characteristics.Type: ApplicationFiled: January 31, 2011Publication date: June 9, 2011Applicant: Wyeth LLCInventors: John C. Clark, John J. Michelucci, Deborah M. Sherman
-
Publication number: 20080124392Abstract: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.Type: ApplicationFiled: January 25, 2008Publication date: May 29, 2008Applicant: WyethInventors: Deborah M. Sherman, John C. Clark, John U. Lamer, Steven A. White
-
Publication number: 20030215507Abstract: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.Type: ApplicationFiled: April 14, 2003Publication date: November 20, 2003Applicant: WyethInventors: Deborah M. Sherman, John C. Clark, John U. Lamer, Steven A. White
-
Publication number: 20020197307Abstract: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.Type: ApplicationFiled: May 21, 2002Publication date: December 26, 2002Applicant: WyethInventors: Deborah M. Sherman, John C. Clark, John U. Lamer, Stephen A. White
-
Patent number: 6419958Abstract: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.Type: GrantFiled: June 19, 2001Date of Patent: July 16, 2002Assignee: WyethInventors: Deborah M. Sherman, John C. Clark, John U. Lamer, Steven A. White
-
Patent number: 6403120Abstract: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and fiber provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.Type: GrantFiled: September 12, 2001Date of Patent: June 11, 2002Assignee: WyethInventors: Deborah M. Sherman, John C. Clark, John U. Lamer, Steven A. White
-
Publication number: 20020025339Abstract: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and fiber provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.Type: ApplicationFiled: September 12, 2001Publication date: February 28, 2002Applicant: American Home Products CorporationInventors: Deborah M. Sherman, John C. Clark, John U. Lamer, Steven A. White
-
Publication number: 20010055612Abstract: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.Type: ApplicationFiled: June 19, 2001Publication date: December 27, 2001Applicant: American Home Products Corporation Five Giralda FarmsInventors: Deborah M. Sherman, John C. Clark, John U. Lamer, Steven A. White
-
Patent number: 6274171Abstract: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.Type: GrantFiled: January 20, 2000Date of Patent: August 14, 2001Assignee: American Home Products CorporationInventors: Deborah M. Sherman, John C. Clark, John U. Lamer, Steven A. White
-
Patent number: 4966768Abstract: A sustained release dosage form of etodolac is provided which is a tablet having as essential components etodolac, hydroxyproplymethylcellulose, ethylcellulose and a release rate modifying agent such as dibasic sodium phosphate, the hydroxyproplymethylcellulose having a hydroxypropoxyl content of about 7.0% to 8.6% by weight.Type: GrantFiled: November 7, 1988Date of Patent: October 30, 1990Assignee: American Home Products CorporationInventors: John J. Michelucci, Deborah M. Sherman, Richard J. DeNeale
-
Patent number: 4781925Abstract: A calcium supplement compressed tablet containing at least about 80% by weight of tricalcium phosphate having incorporated therein as a disintegrant croscarmellose sodium and about 50% to 100% by weight based on the croscarmellose sodium of sodium lauryl sulfate.Type: GrantFiled: March 6, 1986Date of Patent: November 1, 1988Assignee: American Home Products CorporationInventors: John J. Michelucci, Deborah M. Sherman, Ronald N. Warner